You are here

Angiochem to participate in 2010 Bio International Convention


Montreal, Canada – Angiochem a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that it will be participating in a panel session on the discovery and development of breakthrough treatments utilizing innovative chemistry approaches and technologies, taking place on May 5 at the 2010 BIO International Convention in Chicago.

The session, entitled “Challenging the Conventional Wisdom: Re-emergence of Innovative Chemistry for Breakthrough Drugs,” will take place on May 5 at 4:00 pm in Room S401-AB at the McCormick Place convention center.  Jean-Paul Castaigne, M.D., President and CEO of Angiochem, will participate on a panel including companies who will describe novel chemistry approaches and technologies to produce drug candidates with unique product profiles such as Angiochem’s lead oncology product candidate, ANG1005, which leverages the LRP-1 mediated pathway to cross the blood brain barrier and enter tumor cells. 
The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offering key networking and partnering opportunities, and provides insights and inspiration on the major trends in the industry today. For more information on BIO 2010 visit

About ANG1005 // ANG1005 has a novel mode of action, targeting the lipoprotein receptor-related protein (LRP-1) pathway. ANG1005 was  created with the Engineered Peptide Compounds (EPiC) platform which leverages the LRP-1 mediated pathway. Studies have shown that ANG1005 gains entry into the brain by targeting LRP-1, one of the most highly expressed receptors on the surface of the BBB.  ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including gliomas, Breast , Lung, Liver and Ovarian cancers.

About AngioChem // Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier (BBB) to treat brain diseases. The company’s proprietary Engineered Peptide Compounds (EPiC) technology creates drugs that cross the BBB and reach therapeutic concentration in the brain, by harnessing naturally-occurring receptors on the surface of the BBB. Angiochem’s lead product candidate, ANG1005 is in two separate clinical studies in patients with brain cancers and cancer metastases. Additionally, Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the potential treatment of a wide range of CNS diseases, including neurodegenerative and metabolic diseases, brain cancer, psychiatric disorders and many others. Founded in 2006, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit :